Haier Group ("Haier") announced today that it has entered into a strategic cooperation with Killiford (Madrid Stock Exchange stock code: GRF, Madrid Stock Exchange stock code: GR F.P, Nasdaq stock code: GRFS,"Grifols"), a leading global medical and health enterprise and plasma products producer. Based on this strategic cooperation, Haier will purchase 20% of the shares of Shanghai Laishi Blood Products Co., Ltd. (SZ002252,"Shanghai Laishi") held by Killiford for a total price of 12.5 billion RMB and obtain a total of 26.58 of the voting rights. After the transaction is completed, Killiford will continue to hold 6.58 per cent of Shanghai Laishi and retain a seat on the board of directors.

At the same time, Killiford and Shanghai Rex also reached a long-term strategic cooperation agreement. After the completion of the transaction, the term of the exclusive albumin agency agreement signed by Kili Fu and Shanghai Laishi will be extended for ten years, and on this basis, the right to renew for ten years will be obtained.

Haier continues to focus on the real economy and is committed to making technological innovation a new engine of development. In recent years, Haier has focused on the layout of the big health industry track, organically combined scientific and technological innovation with the big health industry, and created the big health ecological brand of Yingkang. Yingkang is committed to the research and development, production and application of high-end scientific research equipment, medical devices and medical service solutions. It has formed an industrial ecology in the fields of plasma blood component collection, storage, preparation, cold chain transportation and clinical application. This transaction will help Yingkang to further improve the layout of the blood ecological industry chain, which is an important milestone in the development of Haier's big health industry.

After the completion of the transaction, Haier will support Shanghai RAAS to continue to increase investment in research and development, and use the Internet of Things scenario solution to optimize supply chain management, promote the digitalization and intelligence of process management from "blood vessels" to "blood vessels", and realize the whole process visualization and value chain promotion. Haier will also use its long-term accumulated advantages in intelligent manufacturing, lean management and corporate governance to empower Shanghai RAAS to meet the urgent needs of society for high-quality blood products with better and safer products.

Tan Lixia, vice chairman of the board of directors and executive vice president of Haier Group, said: "the achievement of this strategic cooperation has further improved the layout of the blood industry chain of Yingkang's life, and is a key process for us to go deep into the core areas of medical and health care. Shanghai RAISE's pursuit of safety, quality and innovation complements Haier's user-centric philosophy of excellence. We look forward to working closely with Shanghai Laishi and Killiford to enhance the integration and innovation of the blood ecological industry chain and contribute to the high-quality development of the health industry. "

China is at the heart of our growth strategy, "said Raimon Grifols, chief corporate officer at Killiford. We are delighted to join forces with Haier, the global leader in innovation, to share our commitment to innovation, quality and safety. With this cooperation, we will be able to support the development of China's health care system with better services, providing innovative drugs and diagnostic solutions for patients. "

Xu Jun, Chairman and General Manager of Shanghai RAAS, said: "We very much welcome Haier's strategic investment in Shanghai RAAS, and thank Haier for its trust in us and confidence in the future development of the industry. Their user-centered concept is highly consistent with our patient-centered concept in Shanghai RAAS. With Haier's advanced management experience and global resource advantages, we will continue to improve product technology and technological innovation capabilities, hoping to become a competitive and innovative company in China and even the world. "

This transaction has been supported by the boards of directors of both parties and is expected to be completed in the first half of 2024. It is subject to customary closing conditions and is subject to regulatory approval and relevant delivery conditions.

--- End ---

Advisory team

China International Capital Corporation and PricewaterhouseCoopers act as joint financial advisers to Haier Group. PricewaterhouseCoopers acted as the overall project management consultant in this transaction and Hanteng Industrial acted as the industry consultant. King & Wood Mallesons acted as Haier Group's legal counsel in this transaction, and Clifford Chance acted as Haier Group's offshore legal counsel.

About Haier Group

Founded in 1984, Haier Group is the world's leading provider of better living and digital transformation solutions. Haier Group has always been user-centered, and has set up 10 R & D centers, 71 research institutes, 35 industrial parks, 138 manufacturing centers and 230000 sales networks around the world. As the world's only Internet of Things ecological brand, Haier Group has been ranked as "BrandZ Top 100 Most Valuable Global Brands" for 5 consecutive years ".

About the whole life of Yingkang

Yingkang Life is Haier Group's big health ecological brand, with Haier Bio (688139.SH) and Yingkang Life (300143.SZ) two listed companies. Yingkang has always focused on the health needs of users throughout its life, and is committed to the research and development, production and application of high-end scientific research equipment, medical devices and medical service solutions. At present, products and services have entered nearly 160 countries and regions in the world.

About Shanghai Rex

Shanghai Laishi was established in 1988. It is a blood product manufacturer with reasonable structure, complete product range and high plasma utilization rate in the same industry in China. The company adheres to the quality policy of "safety, high quality and high efficiency", strictly follows the Drug Administration Law, Drug production quality Management Standard and Chinese Pharmacopoeia, and refers to the relevant laws and regulations of the United States and Europe to establish a sound quality management system. the main products include: human serum albumin, human immunoglobulin (PH4) for intravenous injection, human coagulation factor VIII, human fibrinogen, human prothrombin complex, human thrombin, human fibrin adhesive, etc.

About Killiford

Killifford is a global healthcare company founded in Barcelona in 1909, committed to improving the health and well-being of people around the world. As an industry leader in plasma-derived drugs and transfusion medicine, Kilifook develops, manufactures and delivers innovative healthcare services and solutions in more than 110 countries, focusing on immunology, hepatology and critical care, pulmonology, hematology, neurology and infectious diseases. As a pioneer in the plasma industry, Killiford currently has the world's largest plasma donation network, with more than 390 donation centers in North America, Europe, Africa, the Middle East and China.